Literature DB >> 22607879

Synthesis, enantioresolution, and activity profile of chiral 6-methyl-2,4-disubstituted pyridazin-3(2H)-ones as potent N-formyl peptide receptor agonists.

Agostino Cilibrizzi1, Igor A Schepetkin, Gianluca Bartolucci, Letizia Crocetti, Vittorio Dal Piaz, Maria Paola Giovannoni, Alessia Graziano, Liliya N Kirpotina, Mark T Quinn, Claudia Vergelli.   

Abstract

A series of chiral pyridazin-3(2H)-ones was synthesized, separated as pure enantiomers, and evaluated for N-formyl peptide receptor (FPR) agonist activity. Characterization of the purified enantiomers using combined chiral HPLC and chiroptical studies (circular dichroism, allowed unambiguous assignment of the absolute configuration for each pair of enantiomers). Evaluation of the ability of racemic mixtures and purified enantiomers to stimulate intracellular Ca(2+) flux in FPR-transfected HL-60 cells and human neutrophils and to induce β-arrestin recruitment in FPR-transfected CHO-K1 cells showed that many enantiomers were potent agonists, inducing responses in the sub-micromolar to nanomolar range. Furthermore, FPRs exhibited enantiomer selectivity, generally preferring the R-(-)-forms over the S-(+)-enantiomers. Finally, we found that elongation of the carbon chain in the chiral center of the active compounds generally increased biological activity. Thus, these studies provide important new information regarding molecular features involved in FPR ligand preference and report the identification of a novel series of FPR agonists.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22607879      PMCID: PMC3565387          DOI: 10.1016/j.bmc.2012.04.043

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  36 in total

1.  Integration of virtual screening with high-throughput flow cytometry to identify novel small molecule formylpeptide receptor antagonists.

Authors:  Bruce S Edwards; Cristian Bologa; Susan M Young; Konstantin V Balakin; Eric R Prossnitz; Nikolay P Savchuck; Larry A Sklar; Tudor I Oprea
Journal:  Mol Pharmacol       Date:  2005-08-23       Impact factor: 4.436

2.  Enantioselective nonsteroidal aromatase inhibitors identified through a multidisciplinary medicinal chemistry approach.

Authors:  Andrea Cavalli; Alessandra Bisi; Carlo Bertucci; Carlo Rosini; Anja Paluszcak; Silvia Gobbi; Egidio Giorgio; Angela Rampa; Federica Belluti; Lorna Piazzi; Piero Valenti; Rolf W Hartmann; Maurizio Recanatini
Journal:  J Med Chem       Date:  2005-11-17       Impact factor: 7.446

3.  Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry.

Authors:  J M Kilby; S Hopkins; T M Venetta; B DiMassimo; G A Cloud; J Y Lee; L Alldredge; E Hunter; D Lambert; D Bolognesi; T Matthews; M R Johnson; M A Nowak; G M Shaw; M S Saag
Journal:  Nat Med       Date:  1998-11       Impact factor: 53.440

Review 4.  Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution.

Authors:  Charles N Serhan
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2005 Sep-Oct       Impact factor: 4.006

Review 5.  The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo.

Authors:  Nan Chiang; Charles N Serhan; Sven-Erik Dahlén; Jeffrey M Drazen; Douglas W P Hay; G Enrico Rovati; Takao Shimizu; Takehiko Yokomizo; Charles Brink
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

6.  What formyl peptide receptors, if any, are triggered by compound 43 and lipoxin A4?

Authors:  H Forsman; K Önnheim; E Andreasson; C Dahlgren
Journal:  Scand J Immunol       Date:  2011-09       Impact factor: 3.487

Review 7.  Formyl peptide receptors: a promiscuous subfamily of G protein-coupled receptors controlling immune responses.

Authors:  Isabelle Migeotte; David Communi; Marc Parmentier
Journal:  Cytokine Growth Factor Rev       Date:  2006-11-02       Impact factor: 7.638

8.  Enantioselective chromatography and absolute configuration of N,N-dimethyl-3-(naphthalen-2-yl)-butan-1-amines: potential sigma1 ligands.

Authors:  Simona Collina; Guya Loddo; Mariangela Urbano; Daniela Rossi; Maria Grazia Mamolo; Daniele Zampieri; Stefano Alcaro; Andrea Gallelli; Ornella Azzolina
Journal:  Chirality       Date:  2006-05-05       Impact factor: 2.437

9.  Aspirin-triggered 15-epi-lipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors.

Authors:  T Takano; S Fiore; J F Maddox; H R Brady; N A Petasis; C N Serhan
Journal:  J Exp Med       Date:  1997-05-05       Impact factor: 14.307

10.  Identification and characterization of an endogenous chemotactic ligand specific for FPRL2.

Authors:  Isabelle Migeotte; Elena Riboldi; Jean-Denis Franssen; Françoise Grégoire; Cécile Loison; Valérie Wittamer; Michel Detheux; Patrick Robberecht; Sabine Costagliola; Gilbert Vassart; Silvano Sozzani; Marc Parmentier; David Communi
Journal:  J Exp Med       Date:  2004-12-28       Impact factor: 14.307

View more
  15 in total

Review 1.  Development of small molecule non-peptide formyl peptide receptor (FPR) ligands and molecular modeling of their recognition.

Authors:  I A Schepetkin; A I Khlebnikov; M P Giovannoni; L N Kirpotina; A Cilibrizzi; M T Quinn
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

2.  Synthesis of Five- and Six-Membered N-Phenylacetamido Substituted Heterocycles as Formyl Peptide Receptor Agonists.

Authors:  Claudia Vergelli; Igor A Schepetkin; Giovanna Ciciani; Agostino Cilibrizzi; Letizia Crocetti; Maria Paola Giovannoni; Gabriella Guerrini; Antonella Iacovone; Liliya N Kirpotina; Richard D Ye; Mark T Quinn
Journal:  Drug Dev Res       Date:  2016-11-18       Impact factor: 4.360

3.  Novel formyl peptide receptor (FPR) agonists with pyridinone and pyrimidindione scaffolds that are potentially useful for the treatment of rheumatoid arthritis.

Authors:  Letizia Crocetti; Claudia Vergelli; Gabriella Guerrini; Niccolò Cantini; Liliya N Kirpotina; Igor A Schepetkin; Mark T Quinn; Carmen Parisio; Lorenzo Di Cesare Mannelli; Carla Ghelardini; Maria Paola Giovannoni
Journal:  Bioorg Chem       Date:  2020-04-28       Impact factor: 5.275

4.  Synthesis, HPLC enantioresolution, and X-ray analysis of a new series of C5-methyl pyridazines as N-formyl peptide receptor (FPR) agonists.

Authors:  Agostino Cilibrizzi; Letizia Crocetti; Maria Paola Giovannoni; Alessia Graziano; Claudia Vergelli; Gianluca Bartolucci; Giacomo Soldani; Mark T Quinn; Igor A Schepetkin; Cristina Faggi
Journal:  Chirality       Date:  2013-06-06       Impact factor: 2.437

5.  Novel 3-(1H-indol-3-yl)-2-[3-(4-methoxyphenyl)ureido]propanamides as selective agonists of human formyl-peptide receptor 2.

Authors:  Enza Lacivita; Igor A Schepetkin; Madia L Stama; Liliya N Kirpotina; Nicola A Colabufo; Roberto Perrone; Andrei I Khlebnikov; Mark T Quinn; Marcello Leopoldo
Journal:  Bioorg Med Chem       Date:  2014-12-13       Impact factor: 3.641

6.  Pyridazinones and Structurally Related Derivatives with Anti-Inflammatory Activity.

Authors:  Niccolo Cantini; Igor A Schepetkin; Nadezhda V Danilenko; Andrei I Khlebnikov; Letizia Crocetti; Maria Paola Giovannoni; Liliya N Kirpotina; Mark T Quinn
Journal:  Molecules       Date:  2022-06-10       Impact factor: 4.927

7.  2-Arylacetamido-4-phenylamino-5-substituted pyridazinones as formyl peptide receptors agonists.

Authors:  Claudia Vergelli; Igor A Schepetkin; Giovanna Ciciani; Agostino Cilibrizzi; Letizia Crocetti; Maria Paola Giovannoni; Gabriella Guerrini; Antonella Iacovone; Liliya N Kirpotina; Andrei I Khlebnikov; Richard D Ye; Mark T Quinn
Journal:  Bioorg Med Chem       Date:  2016-04-08       Impact factor: 3.641

8.  3-(1H-indol-3-yl)-2-[3-(4-nitrophenyl)ureido]propanamide enantiomers with human formyl-peptide receptor agonist activity: molecular modeling of chiral recognition by FPR2.

Authors:  Igor A Schepetkin; Liliya N Kirpotina; Andrei I Khlebnikov; Marcello Leopoldo; Ermelinda Lucente; Enza Lacivita; Paola De Giorgio; Mark T Quinn
Journal:  Biochem Pharmacol       Date:  2012-12-03       Impact factor: 5.858

9.  Further studies on 2-arylacetamide pyridazin-3(2H)-ones: design, synthesis and evaluation of 4,6-disubstituted analogs as formyl peptide receptors (FPRs) agonists.

Authors:  Maria Paola Giovannoni; Igor A Schepetkin; Agostino Cilibrizzi; Letizia Crocetti; Andrei I Khlebnikov; Claes Dahlgren; Alessia Graziano; Vittorio Dal Piaz; Liliya N Kirpotina; Serena Zerbinati; Claudia Vergelli; Mark T Quinn
Journal:  Eur J Med Chem       Date:  2013-04-08       Impact factor: 6.514

10.  Correspondence: Reply to 'Compound 17b and formyl peptide receptor biased agonism in relation to cardioprotective effects in ischaemia-reperfusion injury'.

Authors:  Cheng Xue Qin; Lauren T May; Patrick M Sexton; Aaron J DeBono; Jonathan B Baell; Arthur Christopoulos; Rebecca H Ritchie
Journal:  Nat Commun       Date:  2018-02-07       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.